With no buyer for Tryvio, Idorsia claws back $100M from a double-asset deal with Viatris
With the latest hopes of licensing its hypertension drug Tryvio falling through, Idorsia has moved to claw back $100 million in upcoming development costs from a separate licensing deal with Viatris.
With the latest hopes of licensing its hypertension drug Tryvio falling through, Idorsia has moved to claw back $100 million in upcoming development costs from a separate licensing deal with Viatris.
